Antitumor agents. Part 232: Synthesis of cyclosulfite podophyllotoxin analogues as novel prototype antitumor agents

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 6, 2004, Pages 1581-1584

  Xiao, Zhiyan ^a   Han, Shiqing ^a   Bastow, Kenneth F ^a   Lee, Kuo Hsiung ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); PODOPHYLLOTOXIN DERIVATIVE; SULFUR DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; STATISTICAL SIGNIFICANCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PODOPHYLLOTOXIN; SULFITES;

EID: 1542345035     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.12.096     Document Type: Article

References (18)

1. Antitumor Agents 232. For part 231, see: Lee, K. H. J. Nat. Prod., submitted.
2. Schrecker A.W., Hartwell J.L. J. Org. Chem. 21:1956;381.
3. Imbert T.F. Biochimie. 80:1998;207.
4. Jardine I. Anticancer Agents Based on Natural Products Models. 1980;Academic Press, New York. p 319.
5. Issell B.F. Cancer Chemother. Pharmacol. 7:1982;73.
6. Osheroff N., Zechiedrich E.L., Gale K.C. BioEssays. 13:1991;269.
7. Alton P.A., Harris A.L. Br. J. Haematol. 85:1993;241.
8. Zhang Y.L., Lee K.H. Chin. Pharm. J. 46:1994;319.
9. Wang J., Tian X., Tsumura H., Shimura K., Ito H. Anti-Cancer Drug Des. 8:1993;193.
10. Gordaliza M., Del Corral J.M.M., Castro M.A., Lopez-Vazquez M.L., Garcia P.A., Feliciano A.S., Garcia-Gravalos M.D. Bioorg. Med. Chem. Lett. 5:1995;2465.
11. Gordaliza M., Castro M.A., Del Corral J.M.M., Lopez-Vazquez M.L., Garcia P.A., Garcia-Gravalos M.D., Feliciano A.S. Eur. J. Med. Chem. 35:2000;691.
12. Lee K.H. Med. Res. Rev. 19:1999;569.
13. The protocol used to synthesize 9 was similar to that used for its 4′-demethylated congener as previously described in: Zhou X.M., Lee K.J.H., Cheng J., Wu S.S., Chen H.X., Guo X., Cheng Y.C., Lee K.H. J. Med. Chem. 37:1994;287.
14. 2O.
15. 2O.
16. 3), 2.80 (m, 1 2 H, 2-H), 2.62 (m, 1H, 3-H), 2.55 (m, 1 2 H, 2-H).
17. 50 value was interpolated from dose-response data.
18. The plasmid DNA relaxation assay was carried out according to the procedure described previously (Krishnan, P.; Bastow, K. F. Anti-Cancer Drug Des. 2000, 15, 255). Assays were performed with drug concentrations of 50 μM.